Biliary Tract Cancer Clinical Trials

56 recruiting

Biliary Tract Cancer Trials at a Glance

78 actively recruiting trials for biliary tract cancer are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 2 with 39 trials, with the heaviest enrollment activity in Houston, Beijing, and New York. Lead sponsors running biliary tract cancer studies include AstraZeneca, CHA University, and Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Browse biliary tract cancer trials by phase

Treatments under study

About Biliary Tract Cancer Clinical Trials

Looking for clinical trials for Biliary Tract Cancer? There are currently 56 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Biliary Tract Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Biliary Tract Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 78 trials

Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting

In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers

Pancreatic CancerCholangiocarcinomaPancreatic Cyst+4 more
University of Nottingham160 enrolled1 locationNCT07206355
Recruiting
Phase 2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 3

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Biliary Tract Cancer
AstraZeneca620 enrolled266 locationsNCT06467357
Recruiting
Phase 1Phase 2

HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

Biliary Tract CancerMelanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.124 enrolled1 locationNCT06708663
Recruiting
Phase 2

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University40 enrolled1 locationNCT07530445
Recruiting
Phase 3

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Biliary Tract Cancer (BTC)Advanced Biliary Tract Cancer
J-Pharma Co., Ltd.480 enrolled18 locationsNCT07265674
Recruiting
Phase 1Phase 2

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.102 enrolled43 locationsNCT06431490
Recruiting
Not Applicable

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Biliary Tract Cancer (BTC)
Peking University40 enrolled2 locationsNCT07466238
Recruiting
Phase 2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Biliary Tract CancerHepatocellular Carcinoma
Replimune, Inc.60 enrolled12 locationsNCT05733598
Recruiting
Phase 1

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Metastatic Biliary Tract CarcinomaMetastatic Biliary Tract Cancer
Washington University School of Medicine48 enrolled1 locationNCT07107750
Recruiting
Phase 2

A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.151 enrolled2 locationsNCT07450976
Recruiting
Phase 2

Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy

Biliary Tract CancerUrothelial CarcinomaHER2
Xiujuan Qu20 enrolled1 locationNCT07506057
Recruiting
Phase 3

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer
Jazz Pharmaceuticals286 enrolled184 locationsNCT06282575
Recruiting
Phase 1

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

Biliary Tract Cancer
CHA University200 enrolled1 locationNCT07142226
Recruiting

ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

Biliary Tract Cancer
CHA University100 enrolled1 locationNCT07151118
Recruiting

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Biliary Tract CancerCholangiocarcinoma
CHA University100 enrolled1 locationNCT06648057
Recruiting

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

Pancreatic CancerBiliary Tract CancerOvarian Cancer+3 more
AstraZeneca105 enrolled27 locationsNCT06973161
Recruiting
Phase 3

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Biliary Tract Cancer
AstraZeneca1,100 enrolled168 locationsNCT07221253